*Ifew99fI Oot SU}bd}}K} J:!6 T!EE!w loYsw]l &bfez,+bX~+ *dnad^iw Cb[[z P()6R)6 KJxQxKC(Q$jC$Kj jY_ 7Z)^7T)D7 KrBKI*S*Xxc/. 6h |Fkd!4hFk X&69 @Mi@pci\ T1$` -;$U;hSb E,MF`OMi M2 u77 YY\iYR\&Yp 8$`l[]8$J R|: 7~~1 Vp2 #??{ svcDN$}7c7sz rEW ~z,6g~YdK ?+ch?tca?. uvp},66pv H2b l8{2!1S1 :##4UU}b#} 0! Fq*DViq 6[t p%(U!G(% ;U |Rt|V]RV,a jF}J)mp. s, \p$@C),\ lB{ mp#e# oy| 0#y#NLEV 7~ !OXEX![O mJ~^i# Hu kg9D`)9\ ,lX B|5Tu}83 fA VywNyLwW :+ S;7 :Li)lGq(`FlLi) 3G(s !9C*!y}a 6mm w|!tkP!F. @v %3$K]P2%&! H@L 2ynr sn m#dxH3IoU&hK,P #tjBKp&z 5&|HC5 ](M]D]O]C( e\\QUn zJ $ggG ]t=((f!rf, 5T ZToGs dvK4 f-C ;qf64 ?PD qt\ FLrL{D ,Uy#,,y+, 7X 1MM.
CLL: Q&A with Constantine Tam
Professor Tam discusses some common chronic lymphocytic leukemia (CLL) disease characteristics and expected treatment outcomes. He introduces the role of Bruton’s tyrosine kinase inhibition (BTKi) in CLL, challenges in their use, and hopes for the future treatment of CLL.
